. 2013 Jun 12;68(10):2324–2331. doi: 10.1093/jac/dkt203

Table 2.

Patients with oseltamivir-resistant H275Y quasi-species

Patient	Age (years)	Sample week	Region	Quasi-species percentage with Tyr-275 (±SD)		Phenotypic susceptibility (IC₅₀, nM ±SD)		Therapy start to swab (days)	Onset to swab (days)
Patient	Age (years)	Sample week	Region	clinical specimen	cultured isolate	OST	ZAN	Therapy start to swab (days)	Onset to swab (days)
1	50	36	East of England	20.4 (±1.34)^a	NA	ND	ND	2	5
2	40	42	East of England	22.9 (±4.52)	275H only	1.02 (±0.56)	0.64 (±0.27)	3	4
3	8	46	East Midlands	15.9 (±4.82)	12.2 (±1.48)	0.62 (±0.13)	0.43 (±0.12)	3	2
4	5	49	London	14.8 (±1.80)	13.4 (±0.85)	0.98 (±0.24)	0.51 (±0.11)	2^b	3
5	5	50	South East	12.6 (±1.22)	NA	ND	ND	0	4
Sentinel GP	15	44	West Midlands	17.8 (±0.85)^a	NA	ND	ND	0	NK

NA, not available; ND, not done; NK, not known; OST, oseltamivir; ZAN, zanamivir.

^aMean of two tests as there was insufficient material to perform a third.

^bThe patient took only one dose and then stopped due to adverse events (vomiting).